Emzor Pharmaceutical, a Nigerian life sciences manufacturer, has secured nearly $20 million through a five-year bond issuance to expand its production capacity and strengthen regional supply chains.
Bond oversubscribed at 19% yield
The NGN 26.7 billion (USD 19.8 million) Series I bond, issued by Emzor Pharma Funding SPV—a special purpose vehicle created for the transaction—was oversubscribed by more than 106%. The bond carries a 19% coupon and matures five years later. It received approval for trading on the FMDQ Exchange on August 11.
Renaissance Securities (Nigeria) led the arrangement, with FirstCap and UCML Capital co-sponsoring. Nigerian law firm Udo Udoma & Belo-Osagie acted as solicitor to the trustee, where partner Ekundayo Onajobi directed the legal team.
Funds earmarked for Africa’s first antimalarial API plant
Proceeds will finance construction of the continent’s first facility to produce active pharmaceutical ingredients for antimalarial drugs. The capital will also support working capital needs, reinforce supply chains, and boost output across its 120-product portfolio, which includes antibiotics, painkillers, and vitamins.
Emzor started in 1977 as a Lagos retail business before shifting to manufacturing in 1985. This bond issuance forms part of a larger NGN 40 billion debt-finance program designed to scale operations.
Related: Egyptian microfinance firm sold for 95 million
Emeka Okoli, board chair of Emzor Pharma Funding SPV, described the transaction as a key step in deepening local pharmaceutical production. He added that it demonstrated investor confidence in the company’s long-term strategy. FMDQ Group COO Tumi Sekoni said the deal showed how Nigeria’s debt capital markets could support healthcare growth.
Nigerian firms have increasingly turned to bond markets for expansion. Earlier this year, Dangote Petroleum Refinery raised $750 million through an international bond, while Champion Breweries secured $30.7 million in equity. Emzor’s focus on antimalarial APIs distinguishes it—most local manufacturers still depend on imported ingredients, exposing the region to supply chain risks.
Market reaction and long-term outlook
Investors showed strong interest in healthcare-related debt despite Nigeria’s economic challenges. The 19% yield reflects local market conditions and confidence in Emzor’s business model.
The expansion arrives as Nigeria faces drug shortages and rising import costs. Local API production could reduce reliance on foreign suppliers and cut costs for essential medicines. Success might inspire other African manufacturers to develop similar facilities.
Challenges remain. Infrastructure gaps, regulatory delays, and currency fluctuations could hinder progress. For now, the bond issuance marks growing trust in Nigeria’s ability to build its pharmaceutical sector internally.